Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chih-Hung, Shen, Ying-Chun, Shao, Yu-Yun, Hsu, Chiun, Cheng, Ann-Lii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918267/
https://www.ncbi.nlm.nih.gov/pubmed/27508178
http://dx.doi.org/10.2147/JHC.S45040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918267/
https://www.ncbi.nlm.nih.gov/pubmed/27508178
http://dx.doi.org/10.2147/JHC.S45040

Ejemplares similares